Long-term outcomes of biodegradable versus 2nd generation durable polymer drug-eluting stents in PCI: Protocol for a systematic review and meta-analysis
- PMID: 40106519
- PMCID: PMC11922205
- DOI: 10.1371/journal.pone.0319946
Long-term outcomes of biodegradable versus 2nd generation durable polymer drug-eluting stents in PCI: Protocol for a systematic review and meta-analysis
Abstract
Background: More than 3 million individuals globally experience STEMI each year, with percutaneous coronary intervention (PCI) as the preferred revascularization method. While second-generation Drug Eluting Stents (DES) reduce restenosis compared to bare-metal stents, complications such as neoatherosclerosis and stent thrombosis remain. Second-generation stents, including durable polymer (DP-DES) and biodegradable polymer (BP-DES), aim to improve outcomes, though guidelines do not specify a preference. Given mixed results from prior studies and new long-term data, we aim to perform a systematic review and meta-analysis comparing long-term outcomes of DP-DES vs. BP-DES following PCI.
Methods: This protocol has been developed following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. MEDLINE, Embase, and Scopus databases will be searched for eligible observational and interventional studies from inception up to 5th of October 2024. Screening (title/abstract and full text), data extraction, risk of bias assessment, and quality of evidence assessment will be conducted by two independent reviewers. A random-effects model will be used to meta-analyse outcomes.
Discussion: DES have greatly advanced PCI for STEMI. However, long-term stent thrombosis remains an issue due to chronic inflammation and impaired healing from the stent's polymer coating. To overcome this, BP-DES were introduced to dissolve their coating within 2-9 months. However, whether BP-DES offers superior long-term outcomes compared to second-generation DP-DES remains uncertain. While previous meta-analyses have shown similar outcomes, recent studies suggest BP-DES may offer better long-term results. This review will compare long-term outcomes (≥5 years) of BP-DES vs. DP-DES, providing important insights to inform clinical practice. Systematic review registration: PROSPERO (CRD42024592579).
Copyright: © 2025 Thuemmler et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
NSK received funding from the British Heart Foundation for a 4-year PhD.
Similar articles
-
Long-Term Clinical Outcomes of Biodegradable-Polymer Drug-Eluting Stents Versus Second-Generation Durable-Polymer Drug-Eluting Stents for ST-Segment Elevation Myocardial Infarction.Cardiovasc Revasc Med. 2022 Feb;35:98-103. doi: 10.1016/j.carrev.2021.04.014. Epub 2021 Apr 16. Cardiovasc Revasc Med. 2022. PMID: 33893053
-
Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents.JACC Cardiovasc Interv. 2017 Mar 13;10(5):462-473. doi: 10.1016/j.jcin.2016.12.002. JACC Cardiovasc Interv. 2017. PMID: 28279314 Review.
-
Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials.Cardiovasc Interv Ther. 2020 Jul;35(3):250-258. doi: 10.1007/s12928-019-00613-w. Epub 2019 Aug 17. Cardiovasc Interv Ther. 2020. PMID: 31422529
-
Improved clinical outcome with biodegradable polymer drug-eluting stents compared to durable polymer drug-eluting stents for primary percutaneous coronary intervention.Postgrad Med J. 2021 Oct;97(1152):638-643. doi: 10.1136/postgradmedj-2020-138243. Epub 2020 Aug 12. Postgrad Med J. 2021. PMID: 32796116
-
Factors Influencing 1st and 2nd Generation Drug-Eluting Stent Performance: Understanding the Basic Pharmaceutical Drug-in-Polymer Formulation Factors Contributing to Stent Thrombosis Do We Really Need to Eliminate the Polymer?J Pharm Pharm Sci. 2021;24:435-461. doi: 10.18433/jpps32053. J Pharm Pharm Sci. 2021. PMID: 34499602 Review.
References
-
- Byrne RA, Rossello X, Coughlan JJ, et al.. 2023 ESC guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44:3720–826. - PubMed
-
- Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al.. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110(5):588–636. doi: 10.1161/01.CIR.0000134791.68010.FA - DOI - PubMed
-
- Chhabra L, Zain MA, Siddiqui WJ. Angioplasty. BMJ. 2023;321:122.
-
- Giustino G, Colombo A, Camaj A, et al.. Coronary In-Stent Restenosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;80:348–72. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous